Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

Biogen Inc. closed $107.72 short of its 52-week high ($259.93), which the company achieved on January 5th.

Piper Sandler downgraded Biogen (NASDAQ:BIIB) to neutral from overweight on Thursday, citing, among other things, the company ...

In order from steepest decline to narrowest, the five unloved were Intel ( INTC 1.68%), MongoDB ( MDB 0.72%), Biogen ( BIIB 1 ...

The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments.

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Piper Sandler downgraded Biogen (BIIB) to Neutral from Overweight with a price target of $138, down from $315, following a transfer of ...

Biogen Inc. closed $119.28 below its 52-week high ($268.30), which the company reached on January 3rd.

Investing.com -- Jefferies downgraded Biogen (NASDAQ:BIIB) from a Buy to Hold on monday, citing a challenging outlook for 2025. The firm slashed its price target for the stock to $180 from $250 ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to ...

Shares of Biogen Inc. (NASDAQ:BIIB – Get Free Report) have received an average rating of “Hold” from the twenty-nine ...

If we look at 2024’s biggest loser on the Nasdaq 100, it becomes clear that even the mightiest can stumble. The name is Intel ...